Everest Medicines Ltd.'s market cap is currently HK$14.78B. The company's EPS TTM is HK$-3.56; its P/E ratio is ―; Everest Medicines Ltd. is scheduled to report earnings on March 27, 2025, and the estimated EPS forecast is HK$-1.35. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Income Statement
Total Revenue	¥ 125.93M	¥ 12.79M	¥ 54.00K	¥ 0.00	¥ 0.00
Gross Profit	¥ 91.52M	¥ 8.15M	¥ 31.00K	¥ 0.00	¥ 0.00
Operating Income	¥ -932.74M	¥ -1.40B	¥ -1.05B	¥ -688.46M	¥ -176.11M
EBITDA	¥ -744.63M	¥ -198.91M	¥ -972.78M	¥ -683.03M	¥ -195.72M
Net Income	¥ -844.46M	¥ -247.28M	¥ -1.01B	¥ -5.68B	¥ -193.47M
Balance Sheet
Cash & Short-Term Investments	¥ 2.35B	¥ 1.65B	¥ 2.64B	¥ 4.48B	¥ 106.06M
Total Assets	¥ 5.77B	¥ 6.61B	¥ 6.65B	¥ 7.48B	¥ 2.14B
Total Debt	¥ 510.63M	¥ 503.71M	¥ 485.03M	¥ 447.33M	¥ 40.76M
Net Debt	¥ -12.44M	¥ 12.93M	¥ -2.16B	¥ -4.03B	¥ -65.30M
Total Liabilities	¥ 804.10M	¥ 960.25M	¥ 753.83M	¥ 636.11M	¥ 3.00B
Stockholders' Equity	¥ 4.97B	¥ 5.65B	¥ 5.89B	¥ 6.84B	¥ -861.08M
Cash Flow
Free Cash Flow	¥ -1.04B	¥ -1.59B	¥ -1.71B	¥ -991.83M	¥ -181.93M
Operating Cash Flow	¥ -769.19M	¥ -1.16B	¥ -729.94M	¥ -471.90M	¥ -88.66M
Investing Cash Flow	¥ 752.50M	¥ -1.03B	¥ -975.82M	¥ -519.93M	¥ -47.37M
Financing Cash Flow	¥ 10.10M	¥ -25.31M	¥ -76.51M	¥ 5.64B	¥ 62.00M

Currency in CNY

Everest Medicines Ltd. Earnings and Revenue History

Income Statement >

Everest Medicines Ltd. Debt to Assets

Balance Sheet >

Everest Medicines Ltd. Cash Flow

Cash Flow >

Everest Medicines Ltd. Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing